Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO-102 in Advanced MPS IIIA
NCT04088734Phase 2Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Sep 2019
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 3
01
Overview
A Phase 2 trial of rebisufligene etisparvovec in Sanfilippo syndrome type A, sponsored by Ultragenyx Pharmaceutical Inc.. Started Sep 2019; status: terminated.
02
Drugs
rebisufligene etisparvovec
03
Conditions
Sanfilippo syndrome type A
Beyond the preview
Go deeper on NCT04088734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088734.